Search for: "Merck Sharpe & Dohme Corporation"
Results 1 - 20
of 35
Sort by Relevance
|
Sort by Date
25 Jul 2023, 1:43 am
Merck Sharp & Dohme Corp). [read post]
7 Jul 2021, 11:44 pm
The Patentees filed two PTE applications, each of which was based on different goods on the ARTG: Brand Name OPDIVO® KEYTRUDA® Active ingredient nivolumab pembrolizumab Australian sponsor Bristol-Myers Squibb Australia Pty Ltd Merck Sharp & Dohme (Australia) Pty Ltd Relationship between sponsor and patentees Related to one of the patentees Not related to either patentee Date goods containing the drug were first included on ARTG 11 January 2016 16 April 2015… [read post]
18 Feb 2021, 1:19 am
IntroductionOn 9 May 2019, the South African Constitutional Court, the highest appellate court in South Africa, heard its first ever patent litigation case in Ascendis Animal Health (Pty) Limited v Merck Sharpe Dohme Corporation. [read post]
18 Feb 2021, 1:19 am
IntroductionOn 9 May 2019, the South African Constitutional Court, the highest appellate court in South Africa, heard its first ever patent litigation case in Ascendis Animal Health (Pty) Limited v Merck Sharpe Dohme Corporation. [read post]
18 Feb 2021, 1:19 am
IntroductionOn 9 May 2019, the South African Constitutional Court, the highest appellate court in South Africa, heard its first ever patent litigation case in Ascendis Animal Health (Pty) Limited v Merck Sharpe Dohme Corporation. [read post]
18 Feb 2021, 1:19 am
IntroductionOn 9 May 2019, the South African Constitutional Court, the highest appellate court in South Africa, heard its first ever patent litigation case in Ascendis Animal Health (Pty) Limited v Merck Sharpe Dohme Corporation. [read post]
18 Sep 2020, 7:25 am
That said, one is mindful of the fact that as noted by South Africa’s constitutional court in relation to patent validity challenges in Ascendis Animal Health (Pty) Limited v Merck Sharp Dohme Corporation and 2 Other [2019] ZACC 41 (paragraph 100), in the absence of substantive IP examination systems to balance the monopoly conferred by IPRs, validity challenges should be encouraged as they offer an avenue for IPRs to be tested. [read post]
20 Jan 2020, 9:54 am
Day 2 and 3 of the hearing brought premature reports that the the Board of Appeal would be referring questions on priority to the Enlarged Board of Appeal (EBA), with Day 4 ultimately bringing the conclusion that Broad Institute's appeal would be dismissed, due to their patent being found to lack priority.SpecialKat Chijioke Okorie examined the decision of the Constitutional Court of South Africa in Ascendis Animal Health (Pty) Limited v Merck Sharp Dohme… [read post]
13 Jan 2020, 11:56 pm
Late in October last year, the Constitutional Court of South Africa (the ConCourt) handed down its decision on the appropriate default position in patent proceedings in Ascendis Animal Health (Pty) Limited vs Merck Sharp Dohme Corporation and 2 Others [2019] ZACC 41. [read post]
3 Nov 2019, 1:45 pm
The case is Ascendis Animal Health (Pty) Ltd v Merck Sharpe Dohme Corporation and Others. [read post]
27 Jun 2019, 6:15 am
Merck Sharp & Dohme, Case No. 2018-1593 (Fed. [read post]
27 Jun 2019, 6:15 am
Merck Sharp & Dohme, Case No. 2018-1593 (Fed. [read post]
23 May 2019, 3:29 am
Subscript Law offers a graphic explainer for Monday’s opinion in Merck Sharp & Dohme v. [read post]
9 Jan 2019, 4:16 am
Elizabeth McCuskey has this blog’s analysis of Monday’s argument in Merck Sharp & Dohme v. [read post]
7 Jan 2019, 3:58 am
The first is Merck Sharp & Dohme v. [read post]
15 Oct 2018, 12:52 am
The Court of Appeal clarified in Merck v Merck Sharpe & Dohme [2017] EWCA Civ 1834. that this targeting should be considered on an objective basis. [read post]
24 Sep 2018, 1:08 pm
The Supreme Court has agreed to hear the following cases for the upcoming term. [read post]
8 Aug 2018, 1:51 pm
Raines, Kavanaugh wrote for the majority holding in favor of Fannie Mae in a case dealing with a series of accounting failures reported in corporate earning restatements. [read post]
21 Dec 2017, 7:09 am
This work will encompass multiple research projects with the current proposals looking at: the role of price differentials, sector specific impacts and enforcement impacts.BREAKING: CJEU holds that SPCs cannot be obtained on the basis of an "end of procedure notice" pursuant to Article 3(b) SPC RegulationMr Justice Arnold referred two questions to the CJEU on the SPC Regulation in Merck Sharp & Dohme v Comptroller-General of Patents [2016]… [read post]
25 Aug 2017, 3:00 am
Merck Sharp & Dohme, 796 F.3d 1038 (9th Cir. 2015). [read post]
